CVE:PAS Pascal Biosciences (PAS) Stock Price, News & Analysis C$0.02 -0.01 (-25.00%) As of 12/5/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pascal Biosciences Stock (CVE:PAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pascal Biosciences alerts:Sign Up Key Stats Today's RangeC$0.02▼C$0.0250-Day RangeC$0.02▼C$0.0252-Week RangeC$0.02▼C$0.10Volume4,000 shsAverage Volume52,289 shsMarket CapitalizationC$983.85 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. Read More Receive PAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pascal Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PAS Stock News HeadlinesPedro Pascal Tipped To Replace Joaquin Phoenix In Steamy Gay RomanceAugust 28 at 3:34 PM | yahoo.comPedro Pascal in Talks to Star in Todd Haynes' Gay Romance Film After Joaquin Phoenix's Abrupt ExitAugust 28 at 10:33 AM | msn.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)General Hospital’s Kelly Thiebaud on Why Britt & Pascal Will ‘Butt Heads’August 5, 2025 | yahoo.comPedro Pascal at the Fantastic Four Premiere: Did We Get Close?August 5, 2025 | msn.comMaking 'Last of Us' without Pedro Pascal was tough. But Bella Ramsey loves a challengeAugust 5, 2025 | msn.comnVidia launches Pascal graphics for laptopsJuly 20, 2025 | msn.comPedro Pascal’s Stylist Exits After Claiming She Received Death Threats Over One Of His OutfitsJuly 20, 2025 | yahoo.comSee More Headlines PAS Stock Analysis - Frequently Asked Questions How have PAS shares performed this year? Pascal Biosciences' stock was trading at C$0.02 at the beginning of 2025. Since then, PAS shares have increased by 0.0% and is now trading at C$0.02. How do I buy shares of Pascal Biosciences? Shares of PAS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Pascal Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pascal Biosciences investors own include Aurora Cannabis (ACB), Canadian Natural Resources (CNQ), Corus Entertainment (CJR), Cannabis Wheaton Income (CBWTF), Grande West Transportation Group (BUS), Bausch Health Cos (BHC) and Abattis Bioceuticals (ATT). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:PAS CIKN/A Webwww.biommune.net Phone+1-604-6886775FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-340.40% Debt Debt-to-Equity Ratio882.79 Current Ratio0.03 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow55.00 Book ValueC($0.02) per share Price / Book-0.75Miscellaneous Outstanding Shares65,590,000Free FloatN/AMarket CapC$983.85 thousand OptionableNot Optionable Beta1.51 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (CVE:PAS) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pascal Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pascal Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.